Last Price$137.11.5%
Market Cap$237.5B
4.6%
Peers median - 3.1%
15.1%
Peers median - 15.0%
31.4%
Peers median - 35.7%
25.3%
Peers median - 11.2%
Competing with ABT
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$237.5B | 7.0 | $178.0 29.8% undervalued | 15.7% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$145.9B | 6.8 | $35.1 64.6% overvalued | 46.2% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$144.5B | 6.6 | $309.6 18.4% overvalued | 7.0% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 14.6% | 28.4% | |
$121.2B | 6.2 | $118.8 25.7% undervalued | 14.8% | $33.2B | $5,467.0M | 2.7% | 16.5% | 52.7% | 7.4% | 53.6% | |
$41.5B | 6.1 | $56.1 20.2% overvalued | (25.0%) | $5,724.3M | $289.9M | (4.7%) | 5.1% | 78.4% | 21.6% | 7.0% | |
$31.1B | 7.0 | $44.6 42.8% overvalued | (41.6%) | $4,033.0M | $453.9M | 11.3% | 11.3% | 60.4% | 21.7% | 120.3% | |
$25.6B | 5.3 | $72.9 164.5% undervalued | 36.1% | €18.0B | €274.0M | (0.8%) | 1.5% | 43.1% | (4.2%) | 63.4% | |
$22.9B | 6.2 | $208.2 10.5% overvalued | 0.6% | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 1.9% | |
$21.8B | 5.9 | $189.1 75.1% undervalued | (14.5%) | $5,655.4M | $1,132.4M | (23.5%) | 20.0% | 64.3% | 4.5% | 43.0% | |
$17.7B | 7.9 | $93.6 62.8% overvalued | 43.5% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 29.7% | 6.9% | |
$12.9B | 6.1 | $310.3 78.6% undervalued | (44.1%) | $3,999.0M | $622.7M | 3.5% | 15.6% | 70.3% | 14.2% | 2.3% |
Compare ABT Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Abbott LaboratoriesABT
5.8x
4.6%
134.5%
31.9%
Median Peer Set
5.8x
3.7%
21.3%
11.6%
Align Technology, Inc.ALGN
N/A
3.4%
26.0%
11.5%
Boston Scientific CorporationBSX
9.4x
17.6%
16.7%
11.1%
DexCom, Inc.DXCM
7.7x
11.3%
(1.4%)
14.3%
Edwards Lifesciences CorporationEW
6.7x
(9.4%)
202.2%
76.7%
Medtronic plcMDT
4.4x
3.6%
(2.1%)
11.4%
Koninklijke Philips N.V.PHG
1.6x
(0.8%)
83.7%
(3.9%)
Insulet CorporationPODD
8.8x
22.1%
101.7%
20.2%
STERIS plcSTE
4.2x
3.6%
257.9%
7.4%
Stryker CorporationSYK
6.7x
10.2%
(5.8%)
13.2%
Zimmer Biomet Holdings, Inc.ZBH
4.9x
3.8%
(9.4%)
11.8%
Compare ABT Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Abbott Laboratories (ABT) revenue growth compare to peers and the industry?
Abbott Laboratories (ABT) revenue growth is 4.6%, compared to the peers' median of 3.1%.
2. How does Abbott Laboratories (ABT) Free Cash Flow (FCF) margin compare to peers and the industry?
Abbott Laboratories (ABT) FCF margin is 15.1%, compared to the peers' median of 15.0%.
3. How does Abbott Laboratories (ABT) Total Debt to Equity ratio compare to peers and the industry?
Abbott Laboratories (ABT) Total Debt to Equity ratio is 31.4%, compared to the peers' median of 35.7%.
4. How does Abbott Laboratories (ABT) ROIC (Return on Invested Capital) compare to peers and the industry?
Abbott Laboratories (ABT) ROIC is 25.3%, compared to the peers' median of 11.2%.